Mirna Therapeutics, Inc., US private biotechnology company focused on the development and commercialization of micro-RNA based therapeutics, announces scientific publication in PLOS ONE journal (In-Depth Analysis Shows Synergy between Erlotinib and miR-34a) that suggests enhanced potency of lead therapeutic MicroRN-34 in Combination with FDA Approved lung cancer drug erlotinib (Tarceva®) based on in vitro studies.
MicroRNA-34 (miR-34) and erlotinib, an EFGR inhibitor approved to treat non-small cell lung cancer (NSCLC), cooperate synergistically to inhibit proliferation of certain erlotinib-resistant NSCLC cells and hepatocellular carcinoma (HCC) cells in vitro. Other words, miR-34 acts to restore cancer cells sensitivity to erlotinib. Synergic action allowed to significantly reduce effective dose (IC50) of erlotinib.
Mirna is currently conducting a Phase I study of MRX34, a mimic of the naturally-occurring tumor suppressor microRNA miR-34 and the first microRNA replacement therapy product globally to enter a clinical trial in cancer. The Phase I study focuses on patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
The research was supported by a grant from the National Institutes of Health, and a commercialization grant from the Cancer Prevention and Research Institute of Texas (CPRIT).